Formoterol, montelukast, and budesonide in asthmatic children: Effect on lung function and exhaled nitric oxide
详细信息    查看全文
文摘
It has been proposed that asthma control may be achieved in part by minimizing airway inflammation. The simultaneous effects of inhaled steroids associated with long-acting β-agonists and leukotriene antagonists on pulmonary function and airway inflammation are still largely unexplored in children with moderate persistent asthma.

Objectives

The aim of this study was to investigate the effects of add-on therapy with long-acting β-agonists and leukotriene antagonists on FEV1 and exhaled nitric oxide levels (FENO) in children.

Methods

Forty-eight steroid-naïve atopic asthmatic children, 7–11 years of age, were randomly treated in four groups for two consecutive one-month periods, as follows: (1) first month: budesonide 200 μg twice daily; second month: budesonide 400 μg twice daily; (2) first month: budesonide 200 μg twice daily+formoterol 9 μg twice daily; second month: budesonide 200 μg twice daily+montelukast 5 mg once daily; (3) first month: budesonide 200 μg twice daily+montelukast 5 mg once daily; second month budesonide 200 μg+formoterol 9 μg twice daily; (4) first and second month: budesonide 400 μg twice daily.

Results

All treatments resulted in a significant increase in lung function and a decrease in FENO compared with values at baseline. Budesonide+montelukast in combination was the most effective treatment for reducing FENO levels.

Conclusion

This study demonstrates that add-on therapy with montelukast plus low-dose budesonide is more effective than the addition of long-acting β-agonists or doubling the dose of budesonide for controlling FENO in asthmatic children.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700